Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

被引：0
|
作者：
Farber, Harrison W. [1 ]
Germack, Hayley D. [2 ]
Croteau, Nicole S. [3 ]
Simeone, Jason C. [3 ]
Tang, Fei [3 ]
Paoli, Carly J. [2 ]
Doad, Gurinderpal [4 ]
Panjabi, Sumeet [2 ]
De Marco, Teresa [5 ]
机构：
[1] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Cytel, Real World Evidence, Waltham, MA USA
[4] Actelion Pharmaceut, Titusville, NJ USA
[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA
来源：
PULMONARY CIRCULATION | 2024年 / 14卷 / 02期
关键词：
pulmonary arterial hypertension; risk factors; treatment;
D O I：
10.1002/pul2.12326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Epoprostenol for the treatment of pulmonary arterial hypertension
    Cristo Ropero, Maria Jose
    Cruz-Utrilla, Alejandro
    Pilar Escribano-Subias, Maria
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (08) : 1005 - 1013
  • [42] Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension
    Sanchez-Gloria, Jose L.
    Osorio-Alonso, Horacio
    Arellano-Buendia, Abraham S.
    Carbo, Roxana
    Hernandez-Diazcouder, Adrian
    Guzman-Martin, Carlos A.
    Rubio-Gayosso, Ivan
    Sanchez-Munoz, Fausto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (14) : 1 - 35
  • [43] Pharmacologic treatment for pulmonary arterial hypertension
    Sastry, B. K. S.
    CURRENT OPINION IN CARDIOLOGY, 2006, 21 (06) : 561 - 568
  • [44] Tadalafil for the treatment of pulmonary arterial hypertension
    Klinger, James R.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (03) : 315 - 328
  • [45] Treprostinil for the treatment of pulmonary arterial hypertension
    Torres, Fernando
    Rubin, Lewis J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (01) : 13 - 25
  • [46] Medical Treatment of Pulmonary Arterial Hypertension
    Sahay, Sandeep
    Humbert, Marc
    Sitbon, Olivier
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 38 (05) : 686 - 700
  • [47] Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus
    Prabu, Athiveeraramapandian
    Patel, Kiran
    Yee, Chee-Seng
    Nightingale, Peter
    Situnayake, Rohan D.
    Thickett, David R.
    Townend, Jonathan N.
    Gordon, Caroline
    RHEUMATOLOGY, 2009, 48 (12) : 1506 - 1511
  • [48] Macitentan for the treatment of pulmonary arterial hypertension
    Kholdani, Cyrus A.
    Fares, Wassim H.
    Trow, Terence K.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 665 - 673
  • [49] Surgical treatment of pulmonary arterial hypertension
    Fadel, E.
    Mercier, O.
    Mussot, S.
    Fabre, D.
    Humbert, M.
    Simonneau, G.
    Dartevelle, P.
    REVUE DES MALADIES RESPIRATOIRES, 2011, 28 (02) : 139 - 151
  • [50] Pulmonary Arterial Hypertension: Diagnosis and Treatment
    Barnett, Christopher F.
    Alvarez, Paulino
    Park, Myung H.
    CARDIOLOGY CLINICS, 2016, 34 (03) : 375 - +
12345